Inhibitor of HMG-CoA reductase; decreases cholesterol biosynthesis, in vitro and in vivo. Induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Inactive lactam prodrug of mevastatin hydroxy acid, naturally bioactivated in vivo following oral administration.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||9.76||25 with gentle warming|
|DMSO||19.53||50 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 390.52. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.12 mL||25.61 mL||51.21 mL|
|2.5 mM||1.02 mL||5.12 mL||10.24 mL|
|5 mM||0.51 mL||2.56 mL||5.12 mL|
|25 mM||0.1 mL||0.51 mL||1.02 mL|
References are publications that support the biological activity of the product.
Amin-Hanjani et al (2001) Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 980 PMID: 11283400
Cohen et al (1984) Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density lipoprotein-receptor activity in the human hepatoma cell line Hep G2. Biochem.J. 222 35 PMID: 6089762
Wachtershauser et al (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22 1061 PMID: 11408350
If you know of a relevant reference for Mevastatin, please let us know.
View Related Products by Product Action
Keywords: Mevastatin, Mevastatin supplier, HMG-CoA, reductases, inhibitors, inhibits, statins, Compactin, Reductase, 1526, Tocris Bioscience
2 Citations for Mevastatin
Citations are publications that use Tocris products. Selected citations for Mevastatin include:
Vergnes et al (2016) SREBP-2-deficient and hypomorphic mice reveal roles for SREBP-2 in embryonic development and SREBP-1c expression. J Lipid Res 57 410 PMID: 26685326
Brown and Price (2007) Characterization of Salmonella enterica serovar Typhimurium DT104 invasion in an epithelial cell line (IPEC J2) from porcine small intestine. Vet Microbiol 120 328 PMID: 17157450
Do you know of a great paper that uses Mevastatin from Tocris? Please let us know.
Reviews for Mevastatin
There are currently no reviews for this product. Be the first to review Mevastatin and earn rewards!
Have you used Mevastatin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.